{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:49:00Z","timestamp":1793148540100,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"publisher","award":["\u21161024011100004-4-1.6.8;1.6.4;1.6.7;1.6.1"],"award-info":[{"award-number":["\u21161024011100004-4-1.6.8;1.6.4;1.6.7;1.6.1"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12610-3","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:49:23Z","timestamp":1787291363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glucocerebrosidase dysfunction in GBA1 carriers: insights from blood and macrophage analyses"],"prefix":"10.1007","volume":"53","author":[{"given":"Mikhail","family":"Nikolaev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alena","family":"Kopytova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artem","family":"Izyumchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin","family":"Senkevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Artynyuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Pidyurchina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Baydakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Miliukhina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Zakharova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Emelyanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofya","family":"Pchelina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"12610_CR1","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/S41582-024-00999-Z","volume":"20","author":"E Hertz","year":"2024","unstructured":"Hertz E, Chen Y, Sidransky E (2024) Gaucher disease provides a unique window into Parkinson disease pathogenesis. Nat Rev Neurol 20:526\u2013540. https:\/\/doi.org\/10.1038\/S41582-024-00999-Z","journal-title":"Nat Rev Neurol"},{"key":"12610_CR2","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.3390\/genes15121605","volume":"15","author":"C Koros","year":"2024","unstructured":"Koros C, Bougea A, Alefanti I et al (2024) A Global Perspective of GBA1-Related Parkinson\u2019s Disease: A Narrative Review. Genes (Basel) 15:1605. https:\/\/doi.org\/10.3390\/genes15121605","journal-title":"Genes (Basel)"},{"key":"12610_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1002\/MDS.29314","volume":"38","author":"SC Parlar","year":"2023","unstructured":"Parlar SC, Grenn FP, Kim JJ et al (2023) Classification of GBA1 Variants in Parkinson\u2019s Disease: The GBA1-PD Browser. Mov Disord 38:489\u2013495. https:\/\/doi.org\/10.1002\/MDS.29314","journal-title":"Mov Disord"},{"key":"12610_CR4","doi-asserted-by":"publisher","unstructured":"Emelyanov AK, Usenko TS, Tesson C et al (2018) Mutation analysis of Parkinson\u2019s disease genes in a Russian data set. Neurobiol Aging 71. https:\/\/doi.org\/10.1016\/J.NEUROBIOLAGING.2018.06.027","DOI":"10.1016\/J.NEUROBIOLAGING.2018.06.027"},{"key":"12610_CR5","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMOA0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky E, Nalls MA, Aasly JO et al (2009) Multi-center analysis of glucocerebrosidase mutations in Parkinson disease. N Engl J Med 361:1651. https:\/\/doi.org\/10.1056\/NEJMOA0901281","journal-title":"N Engl J Med"},{"key":"12610_CR6","doi-asserted-by":"publisher","first-page":"7102","DOI":"10.3390\/ijms25137102","volume":"25","author":"A Skrahin","year":"2024","unstructured":"Skrahin A, Horowitz M, Istaiti M et al (2024) GBA1-Associated Parkinson\u2019s Disease Is a Distinct Entity. Int J Mol Sci 25:7102. https:\/\/doi.org\/10.3390\/ijms25137102","journal-title":"Int J Mol Sci"},{"key":"12610_CR7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/mds.30141","volume":"40","author":"M Rossi","year":"2025","unstructured":"Rossi M, Schaake S, Usnich T et al (2025) Classification and Genotype\u2013Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review. Mov Disord 40:605\u2013618. https:\/\/doi.org\/10.1002\/mds.30141","journal-title":"Mov Disord"},{"key":"12610_CR8","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1093\/BRAIN\/AWAB371","volume":"145","author":"C Galvagnion","year":"2022","unstructured":"Galvagnion C, Marlet FR, Cerri S et al (2022) Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote \u03b1-synuclein aggregation. Brain 145:1038\u20131051. https:\/\/doi.org\/10.1093\/BRAIN\/AWAB371","journal-title":"Brain"},{"key":"12610_CR9","doi-asserted-by":"publisher","first-page":"31380","DOI":"10.1038\/SREP31380","volume":"6","author":"A Sanchez-Martinez","year":"2016","unstructured":"Sanchez-Martinez A, Beavan M, Gegg ME et al (2016) Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models. Sci Rep 6:31380. https:\/\/doi.org\/10.1038\/SREP31380","journal-title":"Sci Rep"},{"key":"12610_CR10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/MDS.29360","volume":"38","author":"JM den Heijer","year":"2023","unstructured":"den Heijer JM, Cullen VC, Pereira DR et al (2023) A Biomarker Study in Patients with GBA1-Parkinson\u2019s Disease and Healthy Controls. Mov Disord 38:783\u2013795. https:\/\/doi.org\/10.1002\/MDS.29360","journal-title":"Mov Disord"},{"key":"12610_CR11","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1002\/MDS.29132","volume":"37","author":"AE Kopytova","year":"2022","unstructured":"Kopytova AE, Usenko TS, Baydakova GV et al (2022) Could Blood Hexosylsphingosine Be a Marker for Parkinson\u2019s Disease Linked with GBA1 Mutations? Mov Disord 37:1779\u20131781. https:\/\/doi.org\/10.1002\/MDS.29132","journal-title":"Mov Disord"},{"key":"12610_CR12","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1002\/mds.27393","volume":"33","author":"S Pchelina","year":"2018","unstructured":"Pchelina S, Baydakova G, Nikolaev M et al (2018) Blood lysosphingolipids accumulation in patients with parkinson\u2019s disease with glucocerebrosidase 1 mutations. Mov Disord 33:1325\u20131330. https:\/\/doi.org\/10.1002\/mds.27393","journal-title":"Mov Disord"},{"key":"12610_CR13","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/S1474-4422(26)00090-6","volume":"25","author":"E Menozzi","year":"2026","unstructured":"Menozzi E, Toffoli M, Deleidi M et al (2026) New evidence on the clinical, genetic, and biochemical bases of GBA1-Parkinson\u2019s disease: prospects for treatment. Lancet Neurol 25:602\u2013614. https:\/\/doi.org\/10.1016\/S1474-4422(26)00090-6","journal-title":"Lancet Neurol"},{"key":"12610_CR14","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/awu020","volume":"137","author":"A McNeill","year":"2014","unstructured":"McNeill A, Magalhaes J, Shen C et al (2014) Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells. Brain 137:1481\u20131495. https:\/\/doi.org\/10.1093\/brain\/awu020","journal-title":"Brain"},{"key":"12610_CR15","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/mds.28496","volume":"36","author":"M Avenali","year":"2021","unstructured":"Avenali M, Cerri S, Ongari G et al (2021) Profiling the Biochemical Signature of GBA-Related Parkinson\u2019s Disease in Peripheral Blood Mononuclear Cells. Mov Disord 36:1267\u20131272. https:\/\/doi.org\/10.1002\/mds.28496","journal-title":"Mov Disord"},{"key":"12610_CR16","doi-asserted-by":"publisher","first-page":"104620","DOI":"10.1016\/j.nbd.2019.104620","volume":"134","author":"Syu Yang","year":"2020","unstructured":"Yang Syu, Gegg M, Chau D, Schapira A (2020) Glucocerebrosidase activity, cathepsin D and monomeric \u03b1-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation. Neurobiol Dis 134:104620. https:\/\/doi.org\/10.1016\/j.nbd.2019.104620","journal-title":"Neurobiol Dis"},{"key":"12610_CR17","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1093\/BRAIN\/AWV179","volume":"138","author":"RN Alcalay","year":"2015","unstructured":"Alcalay RN, Levy OA, Waters CC et al (2015) Glucocerebrosidase activity in Parkinson\u2019s disease with and without GBA mutations. Brain 138:2648. https:\/\/doi.org\/10.1093\/BRAIN\/AWV179","journal-title":"Brain"},{"key":"12610_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/mds.28792","volume":"37","author":"N Omer","year":"2022","unstructured":"Omer N, Giladi N, Gurevich T et al (2022) Glucocerebrosidase Activity is not Associated with Parkinson\u2019s Disease Risk or Severity. Mov Disord 37:190\u2013195. https:\/\/doi.org\/10.1002\/mds.28792","journal-title":"Mov Disord"},{"key":"12610_CR19","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3390\/CELLS11081261","volume":"11","author":"R Doeppner","year":"2022","unstructured":"Doeppner R, Smith L, Schapira AHV (2022) GBA Variants and Parkinson Disease: Mechanisms and Treatments. Cells 11:1261. https:\/\/doi.org\/10.3390\/CELLS11081261","journal-title":"Cells"},{"key":"12610_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/J.STEMCR.2016.01.013","volume":"6","author":"HJR Fernandes","year":"2016","unstructured":"Fernandes HJR, Hartfield EM, Christian HC et al (2016) ER Stress and Autophagic Perturbations Lead to Elevated Extracellular \u03b1-Synuclein in GBA-N370S Parkinson\u2019s iPSC-Derived Dopamine Neurons. Stem cell Rep 6:342\u2013356. https:\/\/doi.org\/10.1016\/J.STEMCR.2016.01.013","journal-title":"Stem cell Rep"},{"key":"12610_CR21","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1038\/ncomms5028","volume":"5","author":"DC Sch\u00f6ndorf","year":"2014","unstructured":"Sch\u00f6ndorf DC, Aureli M, McAllister FE et al (2014) iPSC-derived neurons from GBA1-associated Parkinson\u2019s disease patients show autophagic defects and impaired calcium homeostasis. Nat Commun 5:4028. https:\/\/doi.org\/10.1038\/ncomms5028","journal-title":"Nat Commun"},{"key":"12610_CR22","doi-asserted-by":"publisher","first-page":"107023","DOI":"10.1016\/J.PARKRELDIS.2024.107023","volume":"124","author":"M Marano","year":"2024","unstructured":"Marano M, Zizzo C, Malaguti MC et al (2024) Increased glucosylsphingosine levels and Gaucher disease in GBA1-associated Parkinson\u2019s disease. Parkinsonism Relat Disord 124:107023. https:\/\/doi.org\/10.1016\/J.PARKRELDIS.2024.107023","journal-title":"Parkinsonism Relat Disord"},{"key":"12610_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1134\/S1990519X19020081","volume":"13","author":"MA Nikolaev","year":"2019","unstructured":"Nikolaev MA, Kopytova AE, Baidakova GV et al (2019) Human Peripheral Blood Macrophages As a Model for Studying Glucocerebrosidase Dysfunction. Cell tissue biol 13:100\u2013106. https:\/\/doi.org\/10.1134\/S1990519X19020081","journal-title":"Cell tissue biol"},{"key":"12610_CR24","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.parkreldis.2021.02.003","volume":"84","author":"AE Kopytova","year":"2021","unstructured":"Kopytova AE, Rychkov GN, Nikolaev MA et al (2021) Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism. Park Relat Disord 84:112\u2013121. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.02.003","journal-title":"Park Relat Disord"},{"key":"12610_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1515\/cclm-2016-0340","volume":"55","author":"G Polo","year":"2017","unstructured":"Polo G, Burlina AP, Kolamunnage TB et al (2017) Diagnosis of sphingolipidoses: A new simultaneous measurement of lysosphingolipids by LC-MS\/MS. Clin Chem Lab Med 55:403\u2013414. https:\/\/doi.org\/10.1515\/cclm-2016-0340","journal-title":"Clin Chem Lab Med"},{"key":"12610_CR26","doi-asserted-by":"publisher","unstructured":"Soria FN SoriaFN\/Lysosome_analysis Lysosome_analysis 1.0. https:\/\/doi.org\/10.5281\/ZENODO.4435278","DOI":"10.5281\/ZENODO.4435278"},{"key":"12610_CR27","doi-asserted-by":"publisher","first-page":"7441","DOI":"10.1523\/JNEUROSCI.0636-16.2016","volume":"36","author":"E Aflaki","year":"2016","unstructured":"Aflaki E, Borger DK, Moaven N et al (2016) A New Glucocerebrosidase Chaperone Reduces \u03b1-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism. J Neurosci 36:7441\u20137452. https:\/\/doi.org\/10.1523\/JNEUROSCI.0636-16.2016","journal-title":"J Neurosci"},{"key":"12610_CR28","doi-asserted-by":"publisher","first-page":"e70214","DOI":"10.1111\/JNC.70214","volume":"169","author":"TS Usenko","year":"2025","unstructured":"Usenko TS, Basharova KS, Bezrukova AI et al (2025) Restoration of Lysosomal Hydrolase Activities by LRRK2 Inhibition in GBA1- and LRRK2-Associated Parkinson\u2019s Disease Patient-Derived Cells. J Neurochem 169:e70214. https:\/\/doi.org\/10.1111\/JNC.70214","journal-title":"J Neurochem"},{"key":"12610_CR29","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3390\/cimb48050473","volume":"48","author":"A Bezrukova","year":"2026","unstructured":"Bezrukova A, Basharova K, Emelyanov A et al (2026) mTOR Inhibition Drives Mutation-Specific Remodeling of Lysosomal and Autophagic Pathways and GCase Activity in PBMC-Derived Macrophages from Patients with GBA1-Associated Parkinson\u2019s Disease. Curr Issues Mol Biol 48:473. https:\/\/doi.org\/10.3390\/cimb48050473","journal-title":"Curr Issues Mol Biol"},{"key":"12610_CR30","doi-asserted-by":"publisher","first-page":"694764","DOI":"10.3389\/FNEUR.2021.694764","volume":"12","author":"E Menozzi","year":"2021","unstructured":"Menozzi E, Schapira AHV (2021) Exploring the Genotype-Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers. Front Neurol 12:694764. https:\/\/doi.org\/10.3389\/FNEUR.2021.694764","journal-title":"Front Neurol"},{"key":"12610_CR31","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.3390\/GENES12101545","volume":"12","author":"T Usenko","year":"2021","unstructured":"Usenko T, Bezrukova A, Basharova K et al (2021) Comparative Transcriptome Analysis in Monocyte-Derived Macrophages of Asymptomatic GBA Mutation Carriers and Patients with GBA-Associated Parkinson\u2019s Disease. Genes (Basel) 12:1545. https:\/\/doi.org\/10.3390\/GENES12101545","journal-title":"Genes (Basel)"},{"key":"12610_CR32","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41531-025-01063-3","volume":"11","author":"E Menozzi","year":"2025","unstructured":"Menozzi E, Lucas S, Pozo D et al (2025) Severe GBA1 variants drive the GBA1-PD clinical phenotype: implications for counselling and clinical trials. npj Park Dis 11:281. https:\/\/doi.org\/10.1038\/s41531-025-01063-3","journal-title":"npj Park Dis"},{"key":"12610_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.17816\/ACEN.1106","volume":"18","author":"A Emelyanov","year":"2024","unstructured":"Emelyanov A, Usenko T, Kopytova A et al (2024) Blood Glucocerebrosidase Activity and \u03b1-Synuclein Levels in Patients with GBA1-Associated Parkinson\u2019s Disease and Asymptomatic GBA1 Mutation Carriers. Ann Clin Exp Neurol 18:50\u201357. https:\/\/doi.org\/10.17816\/ACEN.1106","journal-title":"Ann Clin Exp Neurol"},{"key":"12610_CR34","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jocn.2015.12.004","volume":"28","author":"RA Ortega","year":"2016","unstructured":"Ortega RA, Torres PA, Swan M et al (2016) Glucocerebrosidase Enzyme Activity in GBA Mutation Parkinson Disease HHS Public Access. J Clin Neurosci 28:185\u2013186. https:\/\/doi.org\/10.1016\/j.jocn.2015.12.004","journal-title":"J Clin Neurosci"},{"key":"12610_CR35","doi-asserted-by":"publisher","first-page":"107854","DOI":"10.1016\/j.parkreldis.2025.107854","volume":"135","author":"M Avenali","year":"2025","unstructured":"Avenali M, Caminiti SP, Gegg M et al (2025) Combined assessment of blood glucocerebrosidase activity and \u03b1-synuclein levels in GBA1 mutation carriers: A novel potential biomarker. Park Relat Disord 135:107854. https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107854","journal-title":"Park Relat Disord"},{"key":"12610_CR36","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.3390\/IJMS27041705","volume":"27","author":"S Revel-Vilk","year":"2026","unstructured":"Revel-Vilk S, Szer J, Carubbi F et al (2026) Glucosylsphingosine (Lyso-Gb1): An Update on Its Use as a Biomarker in Gaucher Disease. Int J Mol Sci 27:1705. https:\/\/doi.org\/10.3390\/IJMS27041705","journal-title":"Int J Mol Sci"},{"key":"12610_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/S13023-024-03444-Y","volume":"20","author":"A Zimran","year":"2025","unstructured":"Zimran A, Revel-Vilk S, Dinur T et al (2025) Evaluation of Lyso-Gb1 as a biomarker for Gaucher disease treatment outcomes using data from the Gaucher Outcome Survey. Orphanet J Rare Dis 20:43. https:\/\/doi.org\/10.1186\/S13023-024-03444-Y","journal-title":"Orphanet J Rare Dis"},{"key":"12610_CR38","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","volume":"37","author":"YV Taguchi","year":"2017","unstructured":"Taguchi YV, Liu J, Ruan J et al (2017) Glucosylsphingosine Promotes \u03b1-Synuclein Pathology in Mutant GBA-Associated Parkinson\u2019s Disease. J Neurosci 37:9617\u20139631. https:\/\/doi.org\/10.1523\/JNEUROSCI.1525-17.2017","journal-title":"J Neurosci"},{"key":"12610_CR39","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/MDS.28846","volume":"37","author":"M Surface","year":"2022","unstructured":"Surface M, Balwani M, Waters C et al (2022) Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson\u2019s Disease. Mov Disord 37:416\u2013421. https:\/\/doi.org\/10.1002\/MDS.28846","journal-title":"Mov Disord"},{"key":"12610_CR40","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1002\/mds.70205","volume":"41","author":"J Agin-Liebes","year":"2026","unstructured":"Agin-Liebes J, Haimovich A, Griep R et al (2026) Plasma Glucosylsphingosine in GBA1 E365K, N409S, and L483P Heterozygous Mutation Carriers. Mov Disord 41:1304\u20131309. https:\/\/doi.org\/10.1002\/mds.70205","journal-title":"Mov Disord"},{"key":"12610_CR41","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/S12883-019-1252-3","volume":"19","author":"CRA Silveira","year":"2019","unstructured":"Silveira CRA, MacKinley J, Coleman K et al (2019) Ambroxol as a novel disease-modifying treatment for Parkinson\u2019s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial. BMC Neurol 19:20. https:\/\/doi.org\/10.1186\/S12883-019-1252-3","journal-title":"BMC Neurol"},{"key":"12610_CR42","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/S00415-026-13683-7","volume":"273","author":"M Toffoli","year":"2026","unstructured":"Toffoli M, Menozzi E, Cullen M et al (2026) Protocol of ASPro-PD: a phase 3 trial of ambroxol to slow progression in genetically stratified Parkinson\u2019s disease. J Neurol 273:151. https:\/\/doi.org\/10.1007\/S00415-026-13683-7","journal-title":"J Neurol"},{"key":"12610_CR43","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","volume":"77","author":"S Mullin","year":"2020","unstructured":"Mullin S, Smith L, Lee K et al (2020) Ambroxol for the Treatment of Patients with Parkinson Disease with and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial. JAMA Neurol 77:427\u2013434. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4611","journal-title":"JAMA Neurol"},{"key":"12610_CR44","doi-asserted-by":"publisher","first-page":"23502","DOI":"10.1074\/jbc.M109.012393","volume":"284","author":"GHB Maegawa","year":"2009","unstructured":"Maegawa GHB, Tropak MB, Buttner JD et al (2009) Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease. J Biol Chem 284:23502\u201323516. https:\/\/doi.org\/10.1074\/jbc.M109.012393","journal-title":"J Biol Chem"},{"key":"12610_CR45","unstructured":"Avenali M (2021) Clinical and biochemical signatures of gba-related parkinson disease. Dissertation Univerit\u00e0 Di Pavia"},{"key":"12610_CR46","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1111\/JNC.16114","volume":"168","author":"G Onal","year":"2024","unstructured":"Onal G, Yal\u00e7\u0131n-\u00c7akmakl\u0131 G, \u00d6z\u00e7elik CE et al (2024) Variant-specific effects of GBA1 mutations on dopaminergic neuron proteostasis. J Neurochem 168:2543\u20132560. https:\/\/doi.org\/10.1111\/JNC.16114","journal-title":"J Neurochem"},{"key":"12610_CR47","doi-asserted-by":"publisher","first-page":"240ra73","DOI":"10.1126\/SCITRANSLMED.3008659","volume":"6","author":"E Aflaki","year":"2014","unstructured":"Aflaki E, Stubblefield BK, Maniwang E et al (2014) Macrophage Models of Gaucher Disease for Evaluating Disease Pathogenesis and Candidate Drugs. Sci Transl Med 6:240ra73. https:\/\/doi.org\/10.1126\/SCITRANSLMED.3008659","journal-title":"Sci Transl Med"},{"key":"12610_CR48","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1002\/MDS.27119","volume":"32","author":"P Garc\u00eda-Sanz","year":"2017","unstructured":"Garc\u00eda-Sanz P, Orgaz L, Bueno-Gil G et al (2017) N370S-GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson\u2019s disease. Mov Disord 32:1409\u20131422. https:\/\/doi.org\/10.1002\/MDS.27119","journal-title":"Mov Disord"},{"key":"12610_CR49","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.3390\/ijms24054437","volume":"24","author":"EV Grigor\u2019eva","year":"2023","unstructured":"Grigor\u2019eva EV, Kopytova AE, Yarkova ES et al (2023) Biochemical Characteristics of iPSC-Derived Dopaminergic Neurons from N370S GBA Variant Carriers with and without Parkinson\u2019s Disease. Int J Mol Sci 24:4437. https:\/\/doi.org\/10.3390\/ijms24054437","journal-title":"Int J Mol Sci"},{"key":"12610_CR50","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/J.CELREP.2014.10.023","volume":"9","author":"CM Woodard","year":"2014","unstructured":"Woodard CM, Campos BA, Kuo SH et al (2014) iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson\u2019s disease. Cell Rep 9:1173\u20131182. https:\/\/doi.org\/10.1016\/J.CELREP.2014.10.023","journal-title":"Cell Rep"},{"key":"12610_CR51","doi-asserted-by":"publisher","unstructured":"Collins LM, Drouin-Ouellet J, Kuan WL et al (2017) Dermal fibroblasts from patients with Parkinson\u2019s disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations. https:\/\/doi.org\/10.12688\/F1000RESEARCH.12090.2\/DOI. F1000Research 6:1751","DOI":"10.12688\/F1000RESEARCH.12090.2\/DOI"},{"key":"12610_CR52","doi-asserted-by":"publisher","first-page":"9322","DOI":"10.1073\/PNAS.1500937112","volume":"112","author":"RP McGlinchey","year":"2015","unstructured":"McGlinchey RP, Lee JC (2015) Cysteine cathepsins are essential in lysosomal degradation of \u03b1-synuclein. Proc Natl Acad Sci U S A 112:9322\u20139327. https:\/\/doi.org\/10.1073\/PNAS.1500937112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12610_CR53","doi-asserted-by":"publisher","first-page":"9678","DOI":"10.1021\/BI800699V","volume":"47","author":"D Sevlever","year":"2008","unstructured":"Sevlever D, Jiang P, Yen SHC (2008) Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 47:9678\u20139687. https:\/\/doi.org\/10.1021\/BI800699V","journal-title":"Biochemistry"},{"key":"12610_CR54","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/JNC.14968","volume":"154","author":"M Toffoli","year":"2020","unstructured":"Toffoli M, Smith L, Schapira AHV (2020) The biochemical basis of interactions between Glucocerebrosidase and alpha-synuclein in GBA1 mutation carriers. J Neurochem 154:11\u201324. https:\/\/doi.org\/10.1111\/JNC.14968","journal-title":"J Neurochem"},{"key":"12610_CR55","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41531-022-00397-6","volume":"8","author":"A Navarro-Romero","year":"2022","unstructured":"Navarro-Romero A, Fernandez-Gonzalez I, Riera J et al (2022) Lysosomal lipid alterations caused by glucocerebrosidase deficiency promote lysosomal dysfunction, chaperone-mediated-autophagy deficiency, and alpha-synuclein pathology. NPJ Park Dis 8:126. https:\/\/doi.org\/10.1038\/s41531-022-00397-6","journal-title":"NPJ Park Dis"},{"key":"12610_CR56","doi-asserted-by":"publisher","first-page":"e2406009121","DOI":"10.1073\/PNAS.2406009121","volume":"121","author":"D Williams","year":"2024","unstructured":"Williams D, Glasstetter LM, Jong TT et al (2024) High-throughput screening for small-molecule stabilizers of misfolded glucocerebrosidase in Gaucher disease and Parkinson\u2019s disease. Proc Natl Acad Sci U S A 121:e2406009121. https:\/\/doi.org\/10.1073\/PNAS.2406009121","journal-title":"Proc Natl Acad Sci U S A"},{"key":"12610_CR57","doi-asserted-by":"publisher","first-page":"9454","DOI":"10.3390\/ijms26199454","volume":"26","author":"A Pascual","year":"2025","unstructured":"Pascual A, Moulka T, de F\u00e0bregues O et al (2025) Lysosomal Network Defects in Early-Onset Parkinson\u2019s Disease Patients Carrying Rare Variants in Lysosomal Hydrolytic Enzyme Genes. Int J Mol Sci 26:9454. https:\/\/doi.org\/10.3390\/ijms26199454","journal-title":"Int J Mol Sci"},{"key":"12610_CR58","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/TRA.12587","volume":"19","author":"B Cabukusta","year":"2018","unstructured":"Cabukusta B, Neefjes J (2018) Mechanisms of lysosomal positioning and movement. Traffic 19:761\u2013769. https:\/\/doi.org\/10.1111\/TRA.12587","journal-title":"Traffic"},{"key":"12610_CR59","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1080\/15548627.2024.2413295","volume":"20","author":"Y Sasazawa","year":"2024","unstructured":"Sasazawa Y, Date Y, Hattori N, Saiki S (2024) Clustering lysosomes around the MTOC: a promising strategy for SNCA\/alpha-synuclein breakdown leading to parkinson disease treatment. Autophagy 20:2839\u20132840. https:\/\/doi.org\/10.1080\/15548627.2024.2413295","journal-title":"Autophagy"},{"key":"12610_CR60","doi-asserted-by":"publisher","first-page":"e98649","DOI":"10.7554\/ELIFE.98649","volume":"13","author":"Y Date","year":"2024","unstructured":"Date Y, Sasazawa Y, Kitagawa M et al (2024) Novel autophagy inducers by accelerating lysosomal clustering against Parkinson\u2019s disease. Elife 13:e98649. https:\/\/doi.org\/10.7554\/ELIFE.98649","journal-title":"Elife"},{"key":"12610_CR61","doi-asserted-by":"publisher","first-page":"3432","DOI":"10.1093\/HMG\/DDW185","volume":"25","author":"J Magalhaes","year":"2016","unstructured":"Magalhaes J, Gegg ME, Migdalska-Richards A et al (2016) Autophagic lysosome reformation dysfunction in glucocerebrosidase deficient cells: relevance to Parkinson disease. Hum Mol Genet 25:3432\u20133445. https:\/\/doi.org\/10.1093\/HMG\/DDW185","journal-title":"Hum Mol Genet"},{"key":"12610_CR62","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.4103\/NRR.NRR-D-25-01082","volume":"21","author":"R Wang","year":"2025","unstructured":"Wang R, Hatano T, Hattori N, Cossu D (2025) Interplay of GBA1 with lysosomal dysfunction and inflammation in Parkinson\u2019s disease. Neural Regen Res 21:4803\u20134812. https:\/\/doi.org\/10.4103\/NRR.NRR-D-25-01082","journal-title":"Neural Regen Res"},{"key":"12610_CR63","doi-asserted-by":"publisher","first-page":"108419","DOI":"10.1016\/J.PHARMTHERA.2023.108419","volume":"246","author":"E Menozzi","year":"2023","unstructured":"Menozzi E, Toffoli M, Schapira AHV (2023) Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues. Pharmacol Ther 246:108419. https:\/\/doi.org\/10.1016\/J.PHARMTHERA.2023.108419","journal-title":"Pharmacol Ther"},{"key":"12610_CR64","doi-asserted-by":"publisher","first-page":"201551","DOI":"10.1016\/J.HUMGEN.2026.201551","volume":"48","author":"A Bezrukova","year":"2026","unstructured":"Bezrukova A, Basharova K, Kopytova A et al (2026) Differential gene and protein expression of the mTOR pathway in peripheral blood mononuclear cells distinguishes Parkinson\u2019s disease status in GBA1 mutations carriers. Hum Gene 48:201551. https:\/\/doi.org\/10.1016\/J.HUMGEN.2026.201551","journal-title":"Hum Gene"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12610-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12610-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12610-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:49:25Z","timestamp":1787291365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12610-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12610"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12610-3","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"assertion":[{"value":"21 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the N.P. Bekhtereva Institute of the Human Brain of the Russian Academy of Sciences (November 26, 2020, Protocol No. 1).","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1433"}}